Abstract: Methods of treatment trajectory optimization for radiotherapy treatment of multiple targets include determining beam's eye view (BEV) regions and a BEV region connectivity manifold for each target group of a plurality of target groups separately. The information contained in the BEV regions and the BEV region connectivity manifolds for all target groups is used to guide an optimizer to find optimal treatment trajectories. To improve the visibility of insufficiently exposed voxels of planning target volumes (PTVs), a post-processing step may be performed to enlarge certain BEV regions, which are considered for exposing during treatment trajectory optimization.

Abstract: Methods of beam angle optimization for intensity modulated radiotherapy (IMRT) treatment include determining beam's eye view (BEV) regions and a BEV region connectivity manifold by evaluating dose response of each region of interest for each vertex in a delivery coordinate space (DCS). The information contained in the BEV regions and the BEV region connectivity manifold is used to guide an optimizer to find optimal field geometries in the IMRT treatment. To improve the visibility of insufficiently exposed voxels of planning target volumes (PTVs), a post-processing step may be performed to enlarge certain BEV regions, which are considered for exposing during treatment trajectory optimization.

Abstract: Methods of treatment trajectory optimization for radiotherapy treatment of multiple targets include determining beam's eye view (BEV) regions and a BEV region connectivity manifold for each target group of a plurality of target groups separately. The information contained in the BEV regions and the BEV region connectivity manifolds for all target groups is used to guide an optimizer to find optimal treatment trajectories. To improve the visibility of insufficiently exposed voxels of planning target volumes (PTVs), a post-processing step may be performed to enlarge certain BEV regions, which are considered for exposing during treatment trajectory optimization.

Abstract: Methods of beam angle optimization for intensity modulated radiotherapy (IMRT) treatment include determining beam's eye view (BEV) regions and a BEV region connectivity manifold by evaluating dose response of each region of interest for each vertex in a delivery coordinate space (DCS). The information contained in the BEV regions and the BEV region connectivity manifold is used to guide an optimizer to find optimal field geometries in the IMRT treatment. To improve the visibility of insufficiently exposed voxels of planning target volumes (PTVs), a post-processing step may be performed to enlarge certain BEV regions, which are considered for exposing during treatment trajectory optimization.

Abstract: A polymer comprising at least one unit of the formula (1) wherein T1 is a carbon atom or a nitrogen atom, T2 is a carbon atom if T1 is a nitrogen atom, or is a nitrogen atom if T1 is a carbon atom, r is 1, 2, 3 or 4, s is 1, 2, 3, or 4, M1 is preferably selected from the group consisting of M2 is preferably The polymers are prepared by reacting monomers (1a) with monomers (2a) H2N-[-M1-]r-NH2 (1a) OHC-[-M2-]s-CHO (2a) or the step of reacting monomers (1b) with monomers (2b) OHC-[-M1-]r-CHO (1b) H2N-[-M2-]s-NH2 (2b).

Abstract: Methods of treatment trajectory optimization for radiotherapy treatment of multiple targets include determining beam's eye view (BEV) regions and a BEV region connectivity manifold for each target group of a plurality of target groups separately. The information contained in the BEV regions and the BEV region connectivity manifolds for all target groups is used to guide an optimizer to find optimal treatment trajectories. To improve the visibility of insufficiently exposed voxels of planning target volumes (PTVs), a post-processing step may be performed to enlarge certain BEV regions, which are considered for exposing during treatment trajectory optimization.

Abstract: Methods of beam angle optimization for intensity modulated radiotherapy (IMRT) treatment include determining beam's eye view (BEV) regions and a BEV region connectivity manifold by evaluating dose response of each region of interest for each vertex in a delivery coordinate space (DCS). The information contained in the BEV regions and the BEV region connectivity manifold is used to guide an optimizer to find optimal field geometries in the IMRT treatment. To improve the visibility of insufficiently exposed voxels of planning target volumes (PTVs), a post-processing step may be performed to enlarge certain BEV regions, which are considered for exposing during treatment trajectory optimization.

Abstract: A polymer comprising at least one unit of the formula (1) wherein T1 is a carbon atom or a nitrogen atom, T2 is a carbon atom if T1 is a nitrogen atom, or is a nitrogen atom if T1 is a carbon atom, r is 1, 2, 3 or 4, s is 1, 2, 3, or 4, M1 is preferably selected from the group consisting of M2 is preferably The polymers are prepared by reacting monomers (1a) with monomers (2a) H2N-[-M1-]r-NH2 (1a) OHC-[-M2-]s-CHO (2a) or the step of reacting monomers (1b) with monomers (2b) OHC-[-M1-]r-CHO (1b) H2N-[-M2-]s-NH2 (2b).

Abstract: The present invention features compositions and methods relating to tRNA-derived small RNAs (tsRNAs). Provided herein are oligonucleotide compositions that are complementary to tsRNAs, in particular leuCAGtsRNA, and methods of using the oligonucleotides for the regulation of respective tsRNA. Further provided are methods of inducing apoptosis through the inhibition of leuCAGtsRNA.

Abstract: Novel human interleukin-2 (IL-2) muteins or variants thereof, and nucleic acid molecules and variants thereof are provided. Methods for producing these muteins as well as methods for stimulating the immune system of an animal are also disclosed. In addition, the invention provides recombinant expression vectors comprising the nucleic acid molecules of this invention and host cells into which expression vectors have been introduced. Pharmaceutical compositions are included comprising a therapeutically effective amount of a human IL-2 mutein of the invention and a pharmaceutically acceptable carrier. The IL-2 muteins can be used in pharmaceutical compositions for use in treatment of cancer and in stimulating the immune response.